Generex Biotechnology announced today that its wholly owned subsidiary, Antigen Express, has received Australian Patent No. 778115 titled "Hybrid Peptides Modulate the Immune Response." Antigen Expres
Bionomics Limited announced today that it has filed further patent applications in key markets (including the US) relating to its proprietary cancer drug target BNO69.The role of BNO69 as
Global nanotechnology company pSivida Limited has announced that it has been granted its first patent in China.This first patent grant in China is important as China has the highest incidence
Targeted Genetics Corporation announced today issuance of U.S. patent #6,887,463, entitled, "Methods and Compositions for Gene Therapy for the Treatment of Defects in Lipoprotein Metabolism."
MicroVention announced today that the U.S. Patent and Trademark Office has awarded the company U.S. Patent No. 6,878,384 for its proprietary environmentally-responsive or "smart" hydrogel called
The University of Rochester has filed a patent on several ideas to help prevent early labor and the premature delivery of low-birth-weight babies. The discovery is an incremental step in an area
The University of Rochester has filed a patent on several ideas to help prevent early labor and the premature delivery of low-birth-weight babies. The discovery is an incremental step in an area
Primagen Holding BV has announced that the U.S. Patent and Trademark Office has granted a patent for its Mitox mitochondrial DNA quantification technology as biomarkers for efficacy and adverse events
Neuren Pharmaceuticals has announced that its patent application entitled "GPE Analogs and Peptidomimetics" (PCT/US02/16361) has been issued in the United States (US Patent No: 7,041,314) on 9 May
Shire plc has announced that its subsidiary Shire Laboratories has filed a lawsuit in the U.S. District Court for the District of New Jersey against Corepharma LLC for infringement of some of Shire Labor
Chromos was awarded patents from the United States, Canada and Australia relating to its chromosome-based gene delivery and expression technology known as the ACE System as well as an additional United States patent relating to its REM Technology.
The ACE System is a unique, proprietary artificial chromosome technology used to rapidly engineer cells to express therapeutic proteins. The ACE System provides several unparalleled capabilities for generating cell lines for biopharmaceutical production, for developing gene-based cell therapies and for generating transgenic animals. In the near-term Chromos is focused on using the ACE System to engineer cell lines for biopharmaceutical manufacturing.
The newly issued Australian patent 773,728 contains 198 claims and the recently allowed Canadian patent 2,250,682 contains 250 claims covering Chromos' artificial chromosomes. These patents are of particular relevance as they broadly cover multiple aspects of the ACE System, including satellite artificial chromosomes, the proprietary class of chromosomes used in Chromos' ACE System. In addition, these patents contain specific claims to methods of using the artificial chromosomes for applications in engineering cell lines for biopharmaceutical manufacturing, for gene therapy, and for production of transgenic plants and animals.
The new United States patent 6,743,967 contains broad claims covering the methods of producing non-human transgenic mammals comprising satellite artificial chromosomes. The claims in this patent apply to a range of vertebrate and invertebrate species.
"The broad claims in these additional patents add significant value to our worldwide intellectual property rights surrounding the ACE System and further Chromos' position as a leader in the development and commercialization of artificial chromosome technology," said Alistair Duncan, President and CEO of Chromos. "The growing strength of our patent estate will help us to realize the great commercial potential of the ACE System."
Globally, Chromos owns or exclusively licenses approximately 83 granted patents including 18 granted in the U.S., and has about 70 patent applications pending worldwide. Within its patent estate, Chromos holds a dominant intellectual property portfolio worldwide in mammalian artificial chromosome technologies.
Chromos' REM Technology is a proprietary technology that enables development of immune-based cell therapies using antigen-specific T-cells. This is accomplished by the rapid expansion of a patient's own rare antigen specific T-cells into numbers that will be effective for treatment of specific infectious diseases and cancers. Chromos continues to seek partnering and licensing opportunities for use of its REM Technology for development of therapies to treat these serious diseases.
The patent portfolio related to the REM Technology added a key patent with the issuance of United States patent 6,890,753. This patent contains broad claims to a method for expanding an initial cloned T lymphocyte population in culture. This additional patent significantly broadens Chromos' proprietary patent rights and further demonstrates the unique attributes of the REM Technology in the field of cell-based therapies.
http://www.chromos.com/